Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

Therapeutics for macular edema due to retinal vein occlusion | Clinical Ophthalmology  MD Linx

Ophthalmology Article: Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal ...

Retinal Vein Occlusion Market Analysis & Trends to 2025| Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals  Weekly Wall

Los Angeles, United State, April 10, 2019– The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation ...

Retinal Vein Occlusion Therapeutics Market Research Study including Growth Factors, Types and Application by regions from 2019 to 2023  Current News Magazine

Compare the Retinal Vein Occlusion Therapeutics Market with expected revenue in next Five-Year. The Global Retinal Vein Occlusion Therapeutics Market are ...

Global Retinal Vein Occlusion Market Research Report - Forcast To 2023  Market News Biz

Introduction Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

FDA accepts Outlook Therapeutics' IND for ONS-5010  Seeking Alpha

The FDA accepts Outlook Therapeutics' (OTLK) IND application for ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being ...

Allergan to resume marketing of macular edema treatment  Korea Biomedical Review

Allergan Korea said Tuesday that it has started re-marketing Ozurdex (ingredient: dexamethasone), a steroid eye implant for macular edema.

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article · Related *content* · Metrics ...

Ophthalmic Suspension Market Analysis Revealing Key Drivers, Growth Trends and Competitive Analysis through 2023 |  Medgadget

The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a.

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 12.4% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) now have 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Global Retinal Vein Occlusion Therapeutics Market 2018: Countries, Industry Size, Challenges, Drivers and Technology Forecast to 2023  Washington DC Herald

Retinal Vein Occlusion Therapeutics Market Report will review upcoming market trends with technology advancement, development planning and production ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in ...

Global Retinal Vein Occlusion Therapeutics Market Study 2019-2025: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Crypto News Today

This report analyzes the Global Retinal Vein Occlusion Therapeutics market size (production, value, capacity and consumption) in key regions like North ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

Global Placenta Growth Factor Market 2019 Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd  Times of Market

The “Global Placenta Growth Factor Market 2018 Research Report” is an extensive Placenta Growth Factor Market research report contains an introduction on ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Catheter complications . . . and other stories  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l1045 (Published 14 March 2019) Cite this as: BMJ 2019;364:l1045. Article · Related *content* · Metrics ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Outlook advancing eye disease candidate ONS-5010  Seeking Alpha

Outlook Therapeutics (OTLK -4.5%) has filed an IND with the FDA seeking sign-off to start a U.S. Phase 3 clinical trial evaluating ONS-5010 for the treatment of ...

Ophthalmic Suspension Market 2019 Competitor Analysis By Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited  industryreports24.com

Global Ophthalmic Suspension Market research report is one of the key factors used to maintain competitiveness over competitors. Ophthalmic Suspension ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Allergan's eye implant recalled due to foreign substance  Korea Biomedical Review

Allergan is recalling Ozurdex Intravitreal Implant 700㎍ (ingredient: dexamethasone), a steroid eye implant for macular edema, after detecting a foreign ...

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

Press release *content* from BusinessWire. The AP news staff was not involved in its creation.

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Global Placenta Growth Factor Market Report (2019-2023): Top Companies,Present Demand, Driving Factor Analysis, Trends, Growth Factors, Market Status, Competition Status  regionnewsonline.com

The trending Global “Placenta Growth Factor” research report 2019 represents a comprehensive study of the global market which will enable our customers to ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Macular thickness differentiates occult BRAO, POAG  Healio

Macular scanning may be important in baseline glaucoma evaluation to differentiate occult branch retinal artery occlusion from primary open-angle glaucoma ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Nasdaq

Aerie Pharmaceuticals, Inc. AERI announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone ...

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

Visual Prognosis of Branch Retinal Artery Occlusion  Medscape (subscription)

What is the relationship between initial visual acuity and visual prognosis in patients with branch retinal artery occlusion (BRAO)?

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

Retinal Vein Occlusion Therapeutics Market: Global Distributors, Traders and Dealers Marketing Channel Future Trend Prediction to 2025  Washington DC Herald

Global Retinal Vein Occlusion Therapeutics Market Insights, forecast to 2025 mainly highlights thoughtful facts and knowledge of Retinal Vein Occlusion ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time  FDA Headlines

Oct 16, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right. Regeneron Pharmaceuticals Inc ...

Regeneron Gains on Eylea, Dupixent and Pipeline Progress  Nasdaq

Shares of Regeneron Pharmaceuticals Inc . REGN have gained 3.2% in the year so far against a decline of 5.9% for the industry . Tarrytown,.

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

What is an Eye Stroke? Causes, Symptoms and Treatment  Reports Healthcare

This article aims to explain and create awareness regarding an eye stroke. In depth details of the causes, symptoms and treatment plan are also given.

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA).

Bayer's Eylea cleared for wider use in Europe  PMLiVE

Bayer's eye disease therapy Eylea has been cleared for a new macular oedema indication in the EU, stepping up competition against rival therapy Lucentis from ...

New data comparing Lucentis efficacy and durability versus aflibercept  The Pharma Letter

Swiss pharma giant Novartis (NOVN: VX) today reported new data from a Phase IV head-to-head study (RIVAL) confirming Lucentis (ranibizumab) efficacy and ...

Ranibizumab Outperforms Aflibercept in Efficacy, Durability  MD Magazine

According to the interim results of the RIVAL trial, ranibizumab (Lucentis) showed an increase of 2.2 more letters compared to aflibercept.

Pros and Cons of Compounded Pharmaceuticals | Medpage Today  MedPage Today

This article was adapted from a debate that Julia Haller, MD, and Dante Pieramici, MD, presented at the Retina Subspecialty Day prior to the 2016 American ...

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosi  PharmiWeb.com

Significant visual acuity gains observed in the first year of treatment with aflibercept were largely maintained for 96 weeks· Up to 60% of patients had an injection ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  PR Newswire

HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence ...

A poke in the eye can save your sight: Blindness caused by blood clots can now be cured by a simple jab  Daily Mail

Retinal vein occlusion, clots in a blood vessel in the eye, threatens 17000 people per year who may now be able to sleep easy thanks to a seven minute ...

IRIS Registry Finds New AMD, DME Population Data  MD Magazine

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

Wide-field optical coherence tomography based microangiography for retinal imaging  Nature.com

Optical coherence tomography angiography (OCTA) allows for the evaluation of functional retinal vascular networks without a need for contrast dyes.

Bayer receives approval for Eylea in China  The FINANCIAL

The FINANCIAL -- Bayer announced on May 11 that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory ...

Endophthalmitis Risk Low After Intravitreal Injection  Medscape

The risk for endophthalmitis after intravitreal injection was low, and prophylactic topical antibiotics did not appear to decrease this risk, according to results of a ...

Regeneron Eylea Hits 24-Week Primary Endpoint in Study  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe ...

Bayer receives approval of new treatment regimen for Eylea® in the EU | Antibodies | News Channels  PipelineReview.com

Bayer receives approval of new treatment regimen for Eylea® in the EU.

Vision Loss Reported After Cosmetic Facial Injections  Medscape

Dermal filler injections in the forehead led to vision loss, a rare but devastating event, in 3 patients.

EU expands use of Novartis' eye drug Lucentis  PharmaTimes

The treatment scope of Novartis' Lucentis has been expanded in Europe to include patients with visual impairment due to choroidal neovascularization (CNV) ...

Risk Factors for Cystoid Macular Edema Identified  Medscape

Extensive retinal detachment, advanced age, and use of external drainage were associated with a higher risk for cystoid macular edema after scleral buckling ...

NICE nod for new Eylea indication  PharmaTimes

The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer's Eylea as a treatment for adults for the ...

Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting  PRNewswire

PALO ALTO, Calif., Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel ...

Keeping An Eye On Clearside Biomedical  Seeking Alpha

CLS-TA is an application of Clearside Biomedical's patented suprachoroidal space micro needle injection on triamcinolone acetonide, a steroid drug used for ...

FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of ranibizumab injection (Lucentis, Genentech) to include all forms of diabetic ...

Zeiss receives FDA approval for OCT angiography technology  BioOptics World

Zeiss Medical Technology (Dublin, CA) has received FDA clearance for its AngioPlex OCT angiography technology, which enables ophthalmologists to use ...

Proliferative diabetic retinopathy revealed using OCT angiography  Healio

Diabetic retinopathy is one of the leading causes of vision loss worldwide. Uncontrolled blood glucose levels damage retinal vasculature. Anyone with diabetes ...

Retinal oxygen extraction in humans | Scientific Reports  Nature.com

Adequate function of the retina is dependent on proper oxygen supply. In humans, the inner retina is oxygenated via the retinal circulation. We present a method ...

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  PRNewswire

TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious.

Regeneron, Bayer to co-develop Eylea combination treatment  Reuters

(Reuters) - U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, ...

NICE gives Bayer's Elyea a provisional 'no' for first-line use  PMLiVE

The National Institute of Health and Care Excellence (NICE) is poised to hand Bayer's Eylea a limited recommendation for the treatment of branch retinal vein ...

Ropivacaine: Less Pain, Hemorrhage Risk During Vitrectomy  Medscape

The best intraoperative peribulbar anesthetic during vitrectomy is ropivacaine (1%) compared with bupivacaine, lidocaine, and a solution of bupivacaine and ...

FDA Approves Genentech's Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy  Business Wire

First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) ...

Allergan Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Drops  PR Newswire

DUBLIN, July 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of a new ...

» Load more